QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

23,580 signal articles · 334 in last 24h · 112,379 total before filter · latest 21m ago
334last 24h
2140last 7d
376● bullish (7d)
189● bearish (7d)
204publishers
AllMacro295Earnings1217M&A91Regulatory23Product13Analyst20
✕ clear all filtersticker: MRNAsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
RocketLab Rises on Space Interest; Moderna Moves on Flu Shot | Stock Movers
Bloomberg2d agoneutralVIDEO
RocketLab Rises on Space Interest; Moderna Moves on Flu Shot | Stock Movers

On this episode of Stock Movers: - RocketLab (RKLB) shares are higher this morning after rising Friday, following earnings from SpaceX last week. - Moderna (MRNA) shares are moving after last week's news that its mRNA flu shot won US approval in an FDA turnaround. - Intel (INTC) shares are moving after the company said it will be offering $15 billion in common stock, taking advantage of renewed interest in its business prospects during the artificial intelligence data center boom.

Roivant Sciences Q1 Earnings Call Highlights
MarketBeat5d agoneutral
Roivant Sciences Q1 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline. Chief Executive Officer Matt Gline characterized the quarter as relatively quie

Immunovant Q1 Earnings Call Highlights
MarketBeat6d agoneutral
Immunovant Q1 Earnings Call Highlights

Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant (NASDAQ:IMVT). Chief Executive Officer Matt

Moderna Stock Rises After mRNA Flu Shot Approval
The Wall Street Journal6d agoneutral
Moderna Stock Rises After mRNA Flu Shot Approval

Shares in Moderna ticked higher after the biotech secured Food and Drug Administration approval for its mRNA flu vaccine for use in adults aged 50 and older. The FDA's decision capped an arduous seven-month process that included a rare refusal by the regulator to consider the shot.

FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Review
The Wall Street Journal7d agoneutral
FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Review

The Food and Drug Administration approved Moderna’s mRNA-based flu vaccine for adults ages 50 and older, clearing the first shot of its kind after a review process that nearly collapsed in February. The vaccine, called mFlusiva, uses the same mRNA technology as Moderna’s Covid-19 shots. It could reach pharmacies in time for the coming flu season, which typically starts in the fall.

Moderna Q2 Earnings Call Highlights
MarketBeat12d agoneutral
Moderna Q2 Earnings Call Highlights

Moderna (NASDAQ:MRNA) reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory vaccines, oncology and rare diseases. The company posted a net loss of $782 million, or $1.97 per sha

Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?
StockStory26d agoneutral
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?

The past six months have been a windfall for Moderna’s shareholders. The company’s stock price has jumped 46.4%, hitting $62.97 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Bloomberg26d agoneutral
Neglected Quant Safety Trade Makes a Comeback as AI Risks Rise

(Bloomberg) -- As worries build around the artificial intelligence trade, investors are starting to seek shelter in a more pedestrian corner of the stock market: companies with sturdy finances.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsGoogle Gemini Launch Delayed as Tech Falls Short of Internal GoalsBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthNasdaq Futures Tumble 1.5% as Chip Rout Deepens: Markets WrapUS Cyclospora Outbreak Tied to

US Stock Market Today: S&P 500 Futures Rise As Inflation Cools And Earnings Loom
Simply Wall St.31d agoneutral
US Stock Market Today: S&P 500 Futures Rise As Inflation Cools And Earnings Loom

The Morning Bull - US Market Morning Update Monday, Jul, 13 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 contracts up about 0.4%, as investors digest a mix of cooling inflation and uneven growth signals abroad. Softer price data in countries like France, where inflation sits at 1.8%, suggests global cost of living pressures are easing, which can take some pressure off central banks to keep lifting interest rates. At the same time, weaker industrial output in...

Moderna Shares Up on New Research Efforts for Autoimmune Disorder
The Wall Street Journal47d agoneutral
Moderna Shares Up on New Research Efforts for Autoimmune Disorder

Moderna shares were up more than 10% Friday after the biotech company revealed a new effort to make a treatment for autoimmune disorders and outlined several experimental drug projects that could help it diversify beyond Covid-19 vaccines in coming years.